Dual-responsive nanosystem for precise molecular subtyping and resistant reversal of EGFR targeted therapy
Sign Up to like & getrecommendations! Published in 2019 at "Chemical Engineering Journal"
DOI: 10.1016/j.cej.2019.04.140
Abstract: Abstract The clinical outcome of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors is limited by the ambiguous molecular subtypes of non-small cell lung cancer (NSCLC) patients and the emergence of drug-resistance. Here, a nanotheranostic… read more here.
Keywords: responsive nanosystem; egfr; mutated nsclc; dual responsive ... See more keywords
Investigation of patterns of nodal metastases in BRAF mutant lung cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Lung cancer"
DOI: 10.1016/j.lungcan.2017.02.024
Abstract: Axillary lymph nodes (axLN) are a rare site of nodal metastases in patients with lung cancer. BRAF mutated lung cancer is a genetically distinct subtype that occurs in 2-5% of non-small cell lung carcinomas (NSCLC).… read more here.
Keywords: axln metastases; braf mutated; lung cancer; mutated nsclc ... See more keywords
Abstract 2040: Virtual patient simulation improves first-line treatment selection in advanced EGFR-mutated NSCLC
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.am2020-2040
Abstract: Background: Patients with advanced EGFR-mutated NSCLC benefit from treatment with EGFR TKIs. However, gaps in oncologists9 performance hamper their ability to integrate individualized treatments into the care of patients with this disease. This study was… read more here.
Keywords: egfr mutated; treatment; virtual patient; patient simulation ... See more keywords
Anti–PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC
Sign Up to like & getrecommendations! Published in 2022 at "JCI Insight"
DOI: 10.1172/jci.insight.142843
Abstract: Treatment with anti–PD-1 and anti-PD-L1 therapies has shown durable clinical benefit in non–small cell lung cancer (NSCLC). However, patients with NSCLC with epidermal growth factor receptor (EGFR) mutations do not respond as well to treatment… read more here.
Keywords: cell; anti cd73; anti; anti anti ... See more keywords
Treatment pattern post-osimertinib failure in EGFR mutated NSCLC in India-CRSF202002 study.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.e21201
Abstract: e21201 Background: Osimertinib is one of the favoured treatment options in EGFR mutated NSCLC and was established as a treatment option in last 2-3 years. However the treatment pattern post-osimertinib failure is not established. Hence… read more here.
Keywords: post osimertinib; treatment; failure; mutated nsclc ... See more keywords
Efficacy of Immune Checkpoint Inhibitors in Patients With EGFR Mutated NSCLC and Potential Risk Factors Associated With Prognosis: A Single Institution Experience
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.832419
Abstract: Background The role of immune checkpoint inhibitors (ICIs) in NSCLC patients with EGFR mutations are controversial. In this study, we aim to investigate the therapeutic efficacy of ICIs alone or in combination in patients with… read more here.
Keywords: immune checkpoint; patients egfr; egfr mutated; mutated nsclc ... See more keywords
Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2020.607840
Abstract: Background Molecular profiling of advanced EGFR mutated NSCLC has recently demonstrated the co-existence of multiple genetic alterations. Specifically, co-existing KRAS-mutations in EGFR NSCLCs have been described, despite their prevalence at progression and their role in… read more here.
Keywords: egfr mutated; egfr; first line; nsclc patients ... See more keywords
Gefitinib enhances the anti-tumor immune response against EGFR-mutated NSCLC by upregulating B7H5 expression and activating T cells via CD28H
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Oncology"
DOI: 10.3892/ijo.2022.5436
Abstract: Gefitinib is a sensitive and effective drug to treat non-small-cell lung cancer (NSCLC) carrying the somatic activating mutations of the tyrosine kinase domain of epidermal growth factor receptor (EGFR). In the present study, a new… read more here.
Keywords: egfr mutated; gefitinib; expression; mutated nsclc ... See more keywords